Akso Health Group
Akso Health Group (AHG) Financial Performance & Income Statement Overview
Analyze Akso Health Group (AHG) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Akso Health Group (AHG) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Akso Health Group AHG financial performance.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $760377.00 | $760377.00 | $446792.00 | $446792.00 |
| Cost of Revenue | $718726.00 | $718726.00 | $427377.00 | $427377.00 |
| Gross Profit | $41651.00 | $41651.00 | $19415.00 | $19415.00 |
| Gross Profit Ratio | $0.05 | $0.05 | $0.04 | $0.04 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $3.20M | $3.20M | $1.18M | $1.18M |
| Operating Expenses | $3.20M | $3.07M | $1.54M | $1.54M |
| Total Costs & Expenses | $3.92M | $3.79M | $1.97M | $1.97M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $3.16M | $3.16M | $1.16M | $1.16M |
| EBITDA | $0.00 | $0.00 | $0.00 | $0.00 |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$3.16M | -$3.16M | -$1.16M | -$1.16M |
| Operating Income Ratio | -$4.16 | -$4.16 | -$2.59 | -$2.59 |
| Other Income/Expenses (Net) | $134534.00 | $134534.00 | -$361410.00 | -$361410.00 |
| Income Before Tax | -$3.03M | -$3.03M | -$1.52M | -$1.52M |
| Income Before Tax Ratio | -$3.98 | -$3.98 | -$3.40 | -$3.40 |
| Income Tax Expense | $59.00 | $59.00 | $12435.00 | $12435.00 |
| Net Income | -$3.001M | -$3.00M | -$1.53M | -$1.53M |
| Net Income Ratio | -$3.95 | -$3.94 | -$3.43 | -$3.43 |
| EPS | -$0.14 | -$0.14 | -$0.20 | -$0.20 |
| Diluted EPS | -$0.13 | -$0.13 | -$0.20 | -$0.20 |
| Weighted Avg Shares Outstanding | $20.81M | $20.79M | $7.62M | $7.62M |
| Weighted Avg Shares Outstanding (Diluted) | $23.83M | $23.83M | $7.62M | $7.62M |
Over the last four quarters, Akso Health Group achieved steady financial progress, growing revenue from $446792.00 in Q1 2024 to $760377.00 in Q4 2024. Gross profit stayed firm with margins at 5% in Q4 2024 versus 4% in Q1 2024. Operating income totaled -$3.16M in Q4 2024, maintaining a -416% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $0.00. Net income dropped to -$3.001M, with EPS at -$0.14. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan